Pretreatment characteristics of 595 adult patients with previously untreated AML, by treatment group
| . | DA+GO (n = 295) . | DA (n = 300) . | P* . | ||
|---|---|---|---|---|---|
| Median . | Min–Max . | Median . | Min–Max . | ||
| Age, years | 47 | 18-60 | 48 | 18-60 | .44 |
| White blood cells, 109/L | 10.7 | 0.5-545.0 | 12.5 | 0.2-243.5 | .48 |
| Peripheral blood blasts, % (n = 555) | 34 | 0-99 | 27 | 0-99 | .16 |
| Neutrophils, % (n = 574) | 9 | 0-97 | 10 | 0-72 | .66 |
| Absolute neutrophil count, 109/L (n = 574) | 1.1 | 0-171.6 | 0.9 | 0-40.1 | .32 |
| Hemoglobin, g/dL (n = 583) | 9.1 | 3.5-18.0 | 9.1 | 4.4-29.1 | .81 |
| Platelets, 109/L (n = 593) | 53 | 2-7900 | 55 | 7-9300 | .39 |
| Bone marrow blasts, % (n = 584) | 66 | 7-100 | 65 | 3-100 | .72 |
| Patients | % | Patients | % | ||
| Age, years | |||||
| <35 | 57 | 19% | 56 | 19% | .92 |
| ≥35 | 238 | 81% | 244 | 81% | |
| Sex | |||||
| Female | 135 | 46% | 147 | 49% | .46 |
| Male | 160 | 54% | 153 | 51% | |
| French-American British classification | |||||
| M1 | 67 | 23% | 58 | 20% | .76 |
| M2 | 76 | 26% | 68 | 24% | |
| M4 | 73 | 25% | 71 | 25% | |
| M4eos | 9 | 3% | 10 | 3% | |
| M5 | 38 | 13% | 47 | 16% | |
| M6 | 4 | 1% | 9 | 3% | |
| M7 | 3 | 1% | 3 | 1% | |
| M0 | 21 | 7% | 23 | 8% | |
| Unknown | 4 | — | 11 | — | |
| Performance status | |||||
| 0 | 117 | 40% | 118 | 40% | .37 |
| 1 | 147 | 50% | 136 | 46% | |
| 2 | 22 | 7% | 31 | 10% | |
| 3 | 8 | 3% | 13 | 4% | |
| Unknown | 1 | — | 2 | — | |
| . | DA+GO (n = 295) . | DA (n = 300) . | P* . | ||
|---|---|---|---|---|---|
| Median . | Min–Max . | Median . | Min–Max . | ||
| Age, years | 47 | 18-60 | 48 | 18-60 | .44 |
| White blood cells, 109/L | 10.7 | 0.5-545.0 | 12.5 | 0.2-243.5 | .48 |
| Peripheral blood blasts, % (n = 555) | 34 | 0-99 | 27 | 0-99 | .16 |
| Neutrophils, % (n = 574) | 9 | 0-97 | 10 | 0-72 | .66 |
| Absolute neutrophil count, 109/L (n = 574) | 1.1 | 0-171.6 | 0.9 | 0-40.1 | .32 |
| Hemoglobin, g/dL (n = 583) | 9.1 | 3.5-18.0 | 9.1 | 4.4-29.1 | .81 |
| Platelets, 109/L (n = 593) | 53 | 2-7900 | 55 | 7-9300 | .39 |
| Bone marrow blasts, % (n = 584) | 66 | 7-100 | 65 | 3-100 | .72 |
| Patients | % | Patients | % | ||
| Age, years | |||||
| <35 | 57 | 19% | 56 | 19% | .92 |
| ≥35 | 238 | 81% | 244 | 81% | |
| Sex | |||||
| Female | 135 | 46% | 147 | 49% | .46 |
| Male | 160 | 54% | 153 | 51% | |
| French-American British classification | |||||
| M1 | 67 | 23% | 58 | 20% | .76 |
| M2 | 76 | 26% | 68 | 24% | |
| M4 | 73 | 25% | 71 | 25% | |
| M4eos | 9 | 3% | 10 | 3% | |
| M5 | 38 | 13% | 47 | 16% | |
| M6 | 4 | 1% | 9 | 3% | |
| M7 | 3 | 1% | 3 | 1% | |
| M0 | 21 | 7% | 23 | 8% | |
| Unknown | 4 | — | 11 | — | |
| Performance status | |||||
| 0 | 117 | 40% | 118 | 40% | .37 |
| 1 | 147 | 50% | 136 | 46% | |
| 2 | 22 | 7% | 31 | 10% | |
| 3 | 8 | 3% | 13 | 4% | |
| Unknown | 1 | — | 2 | — | |
Two-sided P value from Wilcoxon test (continuous variables), Fisher’s exact test (age group, sex), or Pearson’s χ-square test (French-American British classification, performance status).